The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains

Table 2 Analysis of the frequency of accessory mutations in RTI-treatment naïve and Q151M-containing sequences on Stanford University HIV database.

^aThe residue occurring in the majority of RTI-treatment naïve patient sequences is referred to as wild-type. Codon positions showing statistically significant difference in mutation frequency between RTI-treatment naïve and Q151M-containing sequences are indicated in bold. Subtype C: I31 (P = 0.033), A33 (P = 0.024), T48 (P < 0.0001), S68 (P < 0.0001), D123 (P = 0.042), Q174 (P = 0.003), I202 (P < 0.0001) and E203 (P = 0.011). Subtype B: I31 (P < 0.0001), A33 (P = 0.024), S68 (P < 0.0001), K102 (P = 0.006), I135 (P = 0.029), Q197 (P = 0.015), I202 (P < 0.0001), E203 (P < 0.0001), T386 (P < 0.0001) and T403 (P = 0.018).
^bSequences containing the Q151M mutation
^cThe number of sequences used for the analysis. Only one sequence was used per individual if multiple sequences were available.
^dThe percentage of sequences with an amino acid change from wild-type residue. The mutant amino acid(s) present at a frequency greater than 1% is shown in brackets.
^eThe difference in mutation frequency between Q151M-containing and RTI-treatment naïve sequences; plus sign indicates an increase and minus sign a decrease in mutation frequency in Q151M-containing sequences compared to RTI-treatment naïve.
^fNC = Not calculated (one sequence available for analysis).
^gNA = Not applicable (no sequences available for analysis).

ISSN: 1742-4690